ImageneBio (IMA) Stock Price, News & Analysis

Company Overview

ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.

Key Stats

• Today's Range: $5.35 to $5.85
• 50-Day Range: $5.25 to $6.11
• 52-Week Range: $3.94 to $18.00
• Volume: 9,278 shs
• Average Volume: 10,094 shs
• Market Capitalization: $61.02 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $26.50
• Consensus Rating: Hold

ImageneBio Stock Analysis - MarketRank™

ImageneBio scored higher than 41% of companies evaluated by MarketBeat, and ranked 598th out of 840 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.4 / 5
• Analyst Rating: Hold

Consensus Rating

ImageneBio has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 2 sell ratings.

Upside Potential

ImageneBio has a consensus price target of $26.50, representing about 362.5% upside from its current price of $5.73.

Amount of Analyst Coverage

ImageneBio has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for ImageneBio are expected to grow in the coming year, from ($3.66) to ($2.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of ImageneBio is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of ImageneBio is -0.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

ImageneBio has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.88% of the float of ImageneBio has been sold short.

Short Interest Ratio / Days to Cover

ImageneBio has a short interest ratio ("days to cover") of 31.53, which indicates bearish sentiment.

Change versus previous month

Short interest in ImageneBio has recently increased by 2.13%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

ImageneBio does not currently pay a dividend.

Dividend Growth

ImageneBio does not have a long track record of dividend growth.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, ImageneBio insiders have not sold or bought any company stock.

Percentage Held by Insiders

2.22% of the stock of ImageneBio is held by insiders.

Percentage Held by Institutions

75.00% of the stock of ImageneBio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/07/2026
• Today: 7/21/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMA
• Previous Symbol: NASDAQ:IMA
• CIK: 1835579
• Web: ikenaoncology.com
• Phone: 857-273-8343
• Fax: N/A
• Employees: 70
• Year Founded: 2016

Price Target and Rating

• Average Price Target for ImageneBio: $26.50
• High Price Target: $30.00
• Low Price Target: $23.00
• Potential Upside/Downside: +362.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.79)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$45.35 million
• Net Margins: N/A
• Pretax Margin: -5,712.38%
• Return on Equity: -38.96%
• Return on Assets: -34.60%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 18.39
• Quick Ratio: 18.39

Sales & Book Value

• Annual Sales: $800 thousand
• Price / Sales: 76.28
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $11.91 per share
• Price / Book: 0.48

Miscellaneous

• Outstanding Shares: 10,650,000
• Free Float: 10,417,000
• Market Cap: $61.02 million
• Optionable: Not Optionable
• Beta: 0.73